George Drew, DO
Dermatology · Marion, OHNPI 1245298009
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,295,139 of the $1,933,193 with a category attached, or 67.0%. It is spread thinly across 46 manufacturers, the largest accounting for just 15.8%. Among dermatology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,152 payments — averaging $613.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$306K
- AbbVie$180K
- E.r. Squibb & Sons, L.L.C.$180K
- Regeneron Healthcare Solutions, Inc.$169K
- Arcutis Biotherapeutics, Inc.$150K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$123K
- plus $825K from 40 others
Across 89 payments — averaging $850.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$24K
- Dermavant Sciences, Inc.$22K
- Boehringer Ingelheim$13K
- Sanofi US Services Inc.$12K
- UCB SA$5K
What the payments were for
- Consulting fees$352,51618%
- Speaking & faculty fees$1,295,13967%
- Travel & lodging$224,50112%
- Food & beverage$59,9423%
- Education$1,0950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,933,193 in reported general payments places this provider in the 95th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 501 | $1,956,849 |
| RinvoqUpadacitinib | 108 | $760,897 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 91 | $751,613 |
| Humira(Cf) PenAdalimumab | 58 | $609,228 |
| Skyrizi PenRisankizumab-Rzaa | 27 | $560,441 |
| TremfyaGuselkumab | 37 | $521,448 |
| Taltz AutoinjectorIxekizumab | 67 | $452,603 |
| SiliqBrodalumab | 66 | $333,177 |
| SkyriziRisankizumab-Rzaa | 13 | $270,727 |
| OpzeluraRuxolitinib Phosphate | 122 | $261,389 |
| Cimzia (2 Pack)Certolizumab Pegol | 22 | $245,874 |
| AdbryTralokinumab-Ldrm | 56 | $194,586 |
| Cosentyx Unoready PenSecukinumab | 12 | $152,436 |
| OtezlaApremilast | 28 | $147,723 |
| SotyktuDeucravacitinib | 23 | $140,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Skyrizi | $180,250 | $1,031,624121 claims |
| Johnson & JohnsonTremfya | $114,447 | $521,44837 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq | $123,148 | $333,17766 claims |
| Incyte CorporationOpzelura | $108,404 | $261,389122 claims |
| UCB, Inc.Cimzia (2 Pack) | $305,770 | $245,87422 claims |
| LEO Pharma Inc.Adbry | $63,877 | $194,58656 claims |
| AmgenOtezla | $417 | $147,72328 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $180,063 | $140,57723 claims |
| Dermavant Sciences, Inc.Vtama | $64,754 | $48,19635 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $150,332 | $34,01540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 460 dermatology providers in Ohio.
Other dermatology in Marion
- Frank MoroccoMarion$202K
- Matthew ZirwasBexley$3.3M
- Rocco SerraoDayton$1.7M
- James LibeccoFairlawn$1.1M
- Pranav ShethWest Chester$978K
- Dawn MerrittAthens$844K
- Neil KormanCleveland$824K
- Joshua GrosshandlerWesterville$479K
- Lorie GottwaldToledo$460K
- Gregory DelostMayfield Heights$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.